| abstract |
The invention relates to the use of reverse transcriptase (RT) inhibiting compounds for the preparation of pharmaceutical compositions for compensating for the loss of cellular differentiation in cancerous and non-cancerous diseases, which compound is capable of binding to the hydrophobic p66 subunit pocket. The following compounds are particularly preferred for these uses: nevirapine, efavirenz, delavirdine, their respective salts and / or pharmaceutically acceptable derivatives. |